Date: 2016-06-23
Type of information: Nomination
Compound:
Company: Vaximm (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 23, 2016, Vaxi announced the election of Thomas Hecht and Mathieu Simon as new members to its Board of Directors. In addition, Dr. Hecht has been appointed as Chairman of the Board, taking over from Dr. Klaus Breiner, who will continue his role in the company as Vice-Chairman.
- Thomas Hecht is a seasoned manager and has extensive experience in the biopharmaceutical industry. Dr. Hecht is founder and owner of Hecht Healthcare Consulting, which provides marketing, clinical development and mergers & acquisitions services to the pharmaceutical/biotechnology industry. Previously, he was VP Marketing (Hematology, Oncology, New Products) at Amgen Europe. Before that, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen Europe. He currently serves as Executive Chairman of Delenex Therapeutics, as Chairman of the Boards of Affimed and Cell Medica , and as Member of the Board of Humabs BioMed. He was previously Chairman of the Boards of ESBATech (acquired by Alcon/Novartis in 2009), SuppreMol (acquired by Baxalta in 2015), and Cytos. Prior to joining the biopharmaceutical industry, Dr. Hecht was certified in internal medicine and served as Co- Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany.
- Mathieu Simon is Executive Vice President, Chief Operating Officer of Cellectis, one of the biopharmaceutical companies leading the development of CAR-T cell immunotherapies. He has been a member of the Cellectis Board of Directors since 2013. Prior to joining Cellectis, he was Senior Vice President Head of Global Pharmaceutical Operations at Pierre Fabre SA. From 1994 to 2010, Dr. Simon served at Wyeth Pharmaceuticals in both senior corporate and regional roles in the US and Europe (Head of International Marketing and Medical Affairs and Managing Director of several Wyeth affiliates). Dr. Simon is an advisor to the European Commission D.G. Research and Innovation. He also serves as Senior Strategic Advisor to Messier Maris Partners, an international investment banking boutique. Dr. Simon was certified in internal medicine at the Faculty of Medicine, Paris VII.
- The following directors will continue to serve on the Board: Dr. Klaus Breiner (BB Biotech Ventures), Vice-Chairman, Dr. Jasper Bos (Merck Ventures), Patrick Burgermeister (BioMedPartners), Dr. Jean- Paul Prieels (independent), and Dr. Sten Verland (Sunstone Capital).
Financial terms:
Latest news:
Is general: Yes
